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Introduction
Small ubiquitin-related modifi  er (SUMO) proteins have been 
implicated in a wide variety of processes (Johnson, 2004). 
  Although budding yeast has a single SUMO, called Smt3p, 
there are three commonly expressed mammalian SUMO para-
logues, called SUMO1, -2, and -3 (Johnson, 2004). SUMO2 
and -3 are 96% identical, whereas SUMO1 is  45% identical 
to   either SUMO2 or -3. (Where they are not distinguishable, 
SUMO2 and -3 are referred to jointly as SUMO2/3 in this 
  paper.) Newly synthesized SUMO proteins are proteolytically 
processed to   expose a C-terminal diglycine motif. Mature 
SUMO proteins are linked to their substrates through an amide 
bond between their C-terminal carboxyl group and an ε-amino 
group of target lysine residues within the substrate. This linkage 
is  accomplished by a pathway that requires an activating  enzyme 
(E1), a conjugating enzyme (E2), and SUMO protein ligases 
(E3s; Melchior et al., 2003; Johnson, 2004). The linkage between 
SUMO proteins and their substrates can be hydrolyzed by 
SUMO proteases (Melchior et al., 2003; Johnson, 2004) and 
may therefore be dynamic in vivo. Individual SUMO paralogues 
appear to play distinct functions in vertebrate cells (Saitoh and 
Hinchey, 2000; Ayaydin and Dasso, 2004), and many substrates 
are modifi   ed in a paralogue-specifi   c fashion (Saitoh and 
Hinchey, 2000; Azuma et al., 2003). Because all paralogues 
share the same E1 and E2 (Johnson, 2004), the selectivity of E3 
enzymes and proteases is likely to play key roles in regulating 
paralogue-specifi  c conjugation patterns.
Ubiquitin forms polymeric chains through the linkage of 
additional ubiquitin moieties to internal lysines of previously 
conjugated ubiquitins. The biological roles of ubiquitin chains 
depend upon the lysines chosen as acceptors during their extension 
(Pickart and Fushman, 2004). Although the prevalence and 
physiological role of SUMO chains have not been established, 
it has been shown that Smt3p, SUMO2, and SUMO3 can 
form chains in vitro and in vivo (Tatham et al., 2001; Bencsath 
et al., 2002; Bylebyl et al., 2003). The major acceptor   lysines 
used in these chains are Lys15 in Smt3p and Lys11 in SUMO2 
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mall ubiquitin-related modiﬁ  er (SUMO) processing 
and deconjugation are mediated by sentrin-speciﬁ  c 
proteases/ubiquitin-like proteases (SENP/Ulps). 
We show that SUMO-speciﬁ   c protease 1 (SUSP1), a 
  mammalian SENP/Ulp, localizes within the nucleoplasm. 
SUSP1 depletion within cell lines expressing enhanced 
green ﬂ  uorescent protein (EGFP) fusions to individual 
SUMO paralogues caused redistribution of EGFP-SUMO2 
and -SUMO3, particularly into promyelocytic leukemia (PML) 
bodies. Further analysis suggested that this change resulted 
primarily from a deﬁ  cit of SUMO2/3-deconjugation activity. 
Under these circumstances, PML bodies became enlarged 
and increased in number. We did not observe a compa-
rable redistribution of EGFP-SUMO1. We have investi-
gated the speciﬁ  city of SUSP1 using vinyl sulfone inhibitors 
and model substrates. We found that SUSP1 has a 
strong paralogue bias toward SUMO2/3 and that it acts 
preferentially on substrates containing three or more 
SUMO2/3 moieties. Together, our ﬁ  ndings argue that 
SUSP1 may play a specialized role in dismantling highly 
conjugated SUMO2 and -3 species that is critical for PML 
body maintenance.
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and -3. Although SUMO1 does not have a conserved lysine at 
the equivalent residue, it can also form chains in vitro through 
an uncharacterized linkage (Pichler and Melchior, 2002). There 
are a limited number of reports indicating that chain formation 
by SUMO2 or -3 is required in vivo for correct regulation of sub-
strate function (Li et al., 2003; Fu et al., 2005). The  promyelocytic 
leukemia protein (PML) is a major SUMO-  conjugation substrate 
and the defi  ning constituent of PML bodies, which are nuclear 
structures of undefi  ned function. It has been reported that the for-
mation of SUMO3 chains may be particularly important for regu-
lation of PML body structure and   dynamics (Fu et al., 2005).
Ulp1p (ubiquitin-like protease 1p) and Ulp2p/Smt4p are 
budding yeast Smt3p proteases that share a conserved catalytic 
domain (Li and Hochstrasser, 1999, 2000). These enzymes are 
not functionally redundant. Ulp1p is likely to have an important 
role in posttranslational processing of Smt3p; overexpression of 
mature Smt3p weakly suppresses ulp1∆ mutants, whereas non-
processed forms of Smt3p do not (Li and Hochstrasser, 1999). 
In contrast, Ulp2p has been implicated in the deconjugation of 
Smt3p from its substrates (Schwienhorst et al., 2000) and, spe-
cifi   cally, in preventing the formation of poly-Smt3p chains 
  (Bylebyl et al., 2003). ulp2∆ cells accumulate high-molecular-
weight Smt3p-containing species, which are lost when conju-
gatable lysine residues within Smt3p are mutated (Bylebyl 
et al., 2003). Additionally, Smt3p mutants that do not form 
chains suppress some ulp2∆ phenotypes (Bylebyl et al., 2003), 
consistent with the notion that those phenotypes arise from 
  inappropriate accumulation of Smt3p chains.
Mammalian proteins related to Ulp1p and -2p have been 
called sentrin-specifi   c proteases (SENPs; Yeh et al., 2000). 
Mammals have seven distinct genes encoding SENP/Ulp fam-
ily members (Yeh et al., 2000; Melchior et al., 2003). Notably, 
some of these gene products act on other ubiquitin-like proteins 
(Gan-Erdene et al., 2003; Wu et al., 2003). Moreover, there are 
distinctions even among the SENP/Ulps that have been verifi  ed 
as SUMO proteases. First, they show distinct localizations 
(Melchior et al., 2003). Second, in vitro studies suggest that 
SENP/Ulps have specialized enzymatic activities. For example, 
SENP2 is signifi  cantly more effi  cient in processing SUMO2 
than SUMO1 or -3 (Reverter and Lima, 2004); although SENP1 
processes SUMO-1 and -2 effi   ciently, it is ineffective for 
  processing of SENP3 (Xu and Au, 2005). In addition, SUMO-
specifi  c protease 1 (SUSP1, also known as SENP6; Yeh et al., 
2000) was reported to act effectively in vitro as a processing 
enzyme but not as a deconjugating enzyme for SUMO1 (Kim 
et al., 2000). The enzymatic specifi  cities of individual SENP/
Ulps have not been systematically evaluated, nor have in vitro 
observations on individual SENP/Ulps been well correlated to 
their in vivo roles.
We have examined the localization, biological function, 
and specifi  city of SUSP1, the largest human SENP/Ulp. We 
found that SUSP1 localizes to the nucleoplasm. Suppression 
of SUSP1 synthesis in cell lines stably expressing EGFP 
  fusions to individual SUMO paralogues caused redistribution 
of EGFP-SUMO2 and -SUMO3 into nuclear foci. A similar 
redistribution was not observed in cells expressing EGFP-
SUMO1. Immunofl  uorescence studies showed that the majority 
of EGFP-SUMO2 and -SUMO3 foci in the SUSP1-depleted 
cells corresponded to PML bodies. Notably, both the size and 
number of PML bodies increased under these circumstances. 
Fusion protein maturation was not required for this redistribu-
tion, suggesting that it resulted primarily from a defi  cit of 
  deconjugation activity. We investigated the enzymatic speci-
fi  city of SUSP1 using vinyl sulfone (VS) inhibitors and model 
substrates. We found that SUSP1 has a strong paralogue 
  preference for SUMO2/3, and particularly for substrates 
  containing three or more SUMO2/3 moieties. Our fi  ndings 
suggest that SUSP1 may play a highly specialized role in 
  dismantling SUMO2 and -3 chains that is critical for PML 
body maintenance.
Figure 1. SUSP1 requires an N-terminal 
  domain for its nucleoplasmic localization. 
(A) HeLa cells were ﬁ  xed, permeabilized, and 
stained for immunoﬂ   uorescence with anti-
SUSP1 antibodies (left). Alternatively, HeLa 
cells were transfected with pEGFP-C1-SUSP1 
(middle) or pEGFP-N1-SUSP1 (right). In all 
cases, DNA was simultaneously visualized 
with Hoechst 33258 dye (insets). (B) HeLa 
cells were transfected with plasmids express-
ing EGFP fusions to fragments of SUSP1. After 
24 h, cell lysates were analyzed by Western 
blotting with anti-GFP antibodies. Lanes were as 
follows: 1, SUSP1
1-84-EGFP (N1); 2, SUSP1
1-263-
EGFP  (N2);  3,  SUSP1
1-449-EGFP  (N3);  4,  SUSP1
1-810-
EGFP (N4); 5, SUSP1
1-930-EGFP (N5); 6, 
SUSP1
84-1112-EGFP (C1); 7, SUSP1
263-1112-
EGFP (C2); 8, SUSP1
449-1112-EGFP (C3); 9, 
SUSP1
810-1112-EGFP (C4); 10, SUSP1
930-1112-
EGFP (C5); and 11, SUSP1
1-1112-EGFP (FL). 
(C) HeLa cells were transfected with GFP   fusion 
constructs N1-N5 and C1-C5 (green). After 
24 h, the cells were ﬁ  xed and counterstained 
with Hoechst 33258 (blue). (D) Schematic summary of the SUSP1 sequences. Predicted NLSs within the full-length protein are indicated by green lines. 
The conserved catalytic domain is indicated in blue. The brown region of bottom bars indicates the nuclear targeting domain. Red lines indicate consensus 
SUMO-binding motifs (Song et al., 2004).SUSP1 CLEAVES SUMO2/3 • MUKHOPADHYAY ET AL. 941
Results
Localization of SUSP1
It has been reported that SUSP1 localizes primarily in the cyto-
plasm (Kim et al., 2000). Because all human SUMO paralogues 
are predominately nuclear (Ayaydin and Dasso, 2004), we reexam-
ined the localization of SUSP1 in HeLa cells (Fig. 1 A) using both 
immunofl  uorescence staining and N- or C-terminal fusions be-
tween SUSP1 and EGFP. All of these approaches clearly indicated 
that SUSP1 is a nucleoplasmic protein, with minimal distribution 
to the cytoplasm, nucleolus, or nuclear envelope. To map the do-
main responsible for its nuclear localization, different fragments 
of SUSP1 were expressed as C-terminal EGFP fusions (Fig. 1 B). 
When we examined their distribution in fi  xed cells, we found that 
sequences between residues 84 and 448 of SUSP1 are required for 
its nuclear localization (Fig. 1, C and D). SUSP1’s localization 
  sequence is notable with respect to targeting sequences of other 
SENP/Ulps: the catalytic domains of all SENP/Ulps are localized 
toward their C termini (Melchior et al., 2003). In every case where 
the targeting requirements of SENP/Ulps have been determined, 
correct localization requires sequences within their N-terminal 
  domains (Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200510103/DC1). Our results for SUSP1 are consistent with 
this pattern, suggesting that the N-terminal domains of SENP/Ulps 
generally mediate their subcellular targeting.
SUSP1 depletion causes redistribution 
of SUMO2 and -3 but not SUMO1
To examine the biological role of SUSP1, its expression 
was suppressed by siRNA-mediated gene silencing in human 
  osteosarcoma-derived cells (U2OS cells) that stably express 
N-terminal EGFP fusions to SUMO1, -2, or -3 (Fig. 2 A). 48 h after 
transfection, cells that were treated with siRNAs against SUSP1 
mRNA showed substantially lower levels of SUSP1 protein 
(<10%) than control cells that were treated with siRNAs di-
rected against Lamin A/C mRNA (Fig. 2 B). In SUSP1-depleted 
cells, EGFP-SUMO1 distribution was indistinguishable from 
Lamin-depleted controls (Fig. 2 A). In contrast, EGFP-SUMO2 
and -SUMO3 showed striking accumulation within nuclear foci 
in  30% of the SUSP1-depleted cells, although this redistribu-
tion was not observed in the control cells. Although the overall 
spectrum of EGFP-SUMO2– or EGFP-SUMO3–conjugated 
  targets detected by Western blotting was not grossly different 
  after depletion of SUSP1, we observed a moderate but consistent 
increase in very high molecular weight GFP-containing species 
(Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200510103/DC1). No comparable accumulation of high 
  molecular weight GFP-containing species occurred in EGFP-
SUMO1–expressing cells (unpublished data). With prolonged 
incubations after siRNA treatment, we observed a higher level 
of cell death in the SUSP1-depleted cells expressing EGFP-
SUMO2 and -SUMO3 than in Lamin-depleted controls (unpub-
lished data), possibly suggesting that the accumulation of such 
SUMO2/3-conjugated species is detrimental to cell survival.
We did not observe redistribution of endogenous SUMO2 
and -3 after SUSP1 depletion by immunofl  uorescence in U2OS 
cells without EGFP-SUMO fusions (unpublished data). The 
most straightforward explanation for this difference is that there 
is suffi  cient SENP activity remaining in SUSP1-depleted cells, 
either from residual SUSP1 or from the redundant activity of 
Figure 2. Deﬁ  cit of SUSP1 deconjugating ac-
tivity causes focal concentration of EGFP-SUMO2 
or -SUMO3. (A) U2OS cells stably expressing 
full-length EGFP-SUMO1, -SUMO2, or -SUMO3 
were transfected with Lamin or SUSP1 siRNA. 
After 48 h, live cell images were acquired. Ap-
proximately 30% of EGFP-SUMO2– or EGFP-
SUMO3–expressing cells showed the speckled 
phenotype after SUSP1 depletion. This phe-
nomenon was never observed in the Lamin-de-
pleted cells or in the EGFP-SUMO1–expressing 
cells. (B) Cells stably expressing EGFP–SUMO3 
were transfected with a plasmid for the synthe-
sis of SUSP1-RFP (pDSRed-N1-Mono-SUSP1), 
encoding by an mRNA with point muta-
tions  that rendered it impervious to RNAi. 
(a) Western blotting analysis with anti-SUSP1 
antibodies (top). Lane 1 shows SUSP1 siRNA 
without rescue, lane 2 shows SUSP1 siRNA 
with rescue, lane 3 shows Lamin siRNA without 
rescue, and lane 4 shows Lamin siRNA with 
rescue. The same membrane was reprobed 
with anti-actin antibodies (bottom), to show 
protein loading. (b) A representative picture 
showing SUSP1-RFP in rescued cells. EGFP-
SUMO3 is in green, SUSP1-RFP is in red, and 
DNA is in blue. (c) The percentage of cells 
showing the EGFP-SUMO3 speckles after 
SUSP1 siRNA and transfection with a control 
plasmid, pDSRed-N1 (−Rescue) or with pD-
SRed-N1-Mono-SUSP1 (+Rescue). Error bars 
represent SD for two separate experiments counting >200 total cells. n = 2. (C) U2OS cells stably expressing mature EGFP-SUMO2 or -SUMO3, ending 
in C-terminal diglycine motifs were transfected with Lamin siRNA or SUSP1 siRNA as in A. (D) U2OS cells stably expressing nonconjugatable EGFP-SUMO2 
or -SUMO3, ending in a single C-terminal glycine were transfected with Lamin or SUSP1 siRNA, as in A. Bars, 10 μM.JCB • VOLUME 174 • NUMBER 7 • 2006  942
other SENP/Ulps, to prevent the inappropriate accumulation 
of conjugated species when SUMO2 and -3 are present at physi-
ological concentrations. In this case, the amount of SUSP1 
  activity may become limiting only when the concentration of 
conjugated species is elevated, as in cells expressing EGFP-
SUMO2 or -SUMO3.
Importantly, redistribution of EGFP-SUMO2 and -SUMO3 
was not observed when siRNAs were cotransfected with a plasmid 
that expresses a fusion between SUSP1 and the red fl  uorescent 
protein (RFP), encoded by a mutant mRNA that is not degraded 
by the siRNAs (Fig. 2 B). This fi  nding substantiates the conclu-
sion that altered EGFP-SUMO2 and -SUMO3 distributions are 
a direct result of SUSP1 depletion. Together, these fi  ndings 
  indicate that SUSP1 plays a paralogue-specifi  c role in the regu-
lation of nucleoplasmic SUMO2/3.
SUSP1 acts as an isopeptidase 
for SUMO2/3 deconjugation
To determine whether the processing function of SUSP1 was 
crucial for the redistribution of EGFP-SUMO2 or -SUMO3, we 
repeated the siRNA experiment in U2OS-derived cell lines 
  stably expressing the processed forms of EGFP-SUMO2 and 
-SUMO3, which terminate with the mature diglycine motif 
(Fig. 2 C). Similar to cells expressing the unprocessed forms, 
EGFP-SUMO2(GG) or -SUMO3(GG) became concentrated 
strongly into nuclear foci. This result implies that accumulation 
of EGFP-SUMO2 or -SUMO3 into foci after SUSP1 depletion 
results from the inability to deconjugate these fusion proteins 
from their substrates rather than insuffi  cient processing  capacity. 
Consistent with this conclusion, we observed no redistribution 
after siRNA of nonconjugatable EGFP-SUMO2 or -SUMO3 
that had only a single C-terminal glycine (Fig. 2 D).
EGFP-SUMO2 and -SUMO3 accumulate 
in PML bodies after SUSP1 depletion
Together, our results suggested that insuffi  cient levels of SUSP1 
deconjugation activity caused the accumulation of EGFP-
SUMO2 and -SUMO3 in nuclear foci. It was therefore of inter-
est to characterize these structures. First, we examined the size 
of EGFP-SUMO2– or EGFP-SUMO3–labeled foci in cells de-
pleted of SUSP1 or Lamin A/C (Fig. 3). We observed a bimodal 
distribution of foci size in the SUSP1-depleted cells, with a sub-
stantial peak of larger foci centered  0.8 μm in diameter. There 
were very few foci of this size in the Lamin-depleted cells.
We reasoned that these foci might correspond to nuclear 
subcompartments where SUMO2/3 normally play a physiologi-
cal role. To test this idea, we stained SUSP1-depleted cells with 
a variety of antibodies that recognize antigens characteristic of 
splicing foci (SC35; Huang and Spector, 1991), pericentric het-
erochromatin (trimethyl-Histone H3 [Lys9]; Peters et al., 2003), 
and centromeres (CREST sera; Earnshaw and Rothfi  eld, 1985). 
We did not observe colocalization of EGFP-SUMO2/3 with 
  either SC35 or trimethyl-Histone H3 (unpublished data). We 
observed some colocalization with CREST sera staining, but 
the extent of this accumulation was not substantially different 
between SUSP1-depleted and control cells (unpublished data). 
We also stained the cells with antibodies directed against a variety 
of SUMO substrates, including Bloom’s antigen (BLM), Wilms’ 
tumor 1 (WT1), proliferating cell nuclear antigen (PCNA), 
p300, and PML (Johnson, 2004; Smolen et al., 2004). We did 
not fi  nd redistribution of BLM, WT1, PCNA, or p300, nor their 
accumulation within the EGFP-SUMO2/3 foci (unpublished 
data). However, we saw a substantial increase in the number of 
PML bodies after SUSP1 depletion and extensive colocaliza-
tion of PML with EGFP-SUMO2 or -SUMO3 (Fig. 3 A).
Comparison of PML bodies versus EGFP-SUMO3 foci 
(Fig. 3 B) showed that the size distribution of PML bodies after 
SUSP1 depletion mirrored the change in EGFP-SUMO3 foci. 
Indeed, the larger EGFP-SUMO3 foci in SUSP1-depleted cells 
almost universally correlated to PML-containing structures 
(Fig. 3 A), suggesting that enlarged PML bodies result from in-
suffi  cient SUMO2/3 deconjugation after SUSP1 depletion. The 
smaller, non–PML-containing bodies may analogously repre-
sent other structures to which SUMO2/3 conjugates associate 
under normal circumstances.
SUSP1 acts speciﬁ  cally as a SUMO2/3 
protease in vitro
To directly determine the paralogue specifi  city of SUSP1, we 
used VS derivatives of tagged SUMO1 and -2 (HA-SU1-VS 
and HA-SU2-VS; Hemelaar et al., 2004). VS reagents derived 
Figure 3.  Large EGFP-SUMO3 speckles in SUSP1-depleted cells colocalize 
with PML. (A) U2OS cells expressing EGFP-SUMO3 (green) were treated 
with Lamin or SUSP1 siRNA as indicated. The cells were ﬁ  xed, permeabi-
lized, and stained with anti-PML antibodies (red). Merged images are 
shown on right. (B) The diameters of EGFP-SUMO3 foci in SUSP1-depleted 
(a) and Lamin-depleted (b) cells were measured. These distributions were 
compared with the size distribution of foci containing (yellow bars) or lack-
ing (green bars) colocalized PML in SUSP1-depleted (c) and Lamin-  depleted 
(d) cells. Bar, 10 μM.SUSP1 CLEAVES SUMO2/3 • MUKHOPADHYAY ET AL. 943
from ubiquitin-like proteins covalently react with the nucleo-
philic active site residues of their respective modifying en-
zymes, showing considerable preference toward deconjugation 
enzymes over E1 and E2 enzymes. To test the reactivity of 
SUSP1 for SUMO1 and -2, extracts of control and SUSP1-
  depleted U2OS cells were incubated with HA-SU1-VS or HA-
SU2-VS. Samples were taken at different times and subjected to 
SDS-PAGE and Western blotting with anti-HA antibodies (Fig. 
4 A). We observed a band in HA-SU2-VS–treated control ex-
tracts that migrated with an apparent molecular mass of  160 kD. 
This band was absent in the SUSP1-depleted extracts. Both the 
molecular mass of this band and its depletion through RNAi 
  indicate that it was derived from a covalent attachment of 
HA-SU2-VS and SUSP1. Moreover, when we immunoblotted 
the same samples with anti-SUSP1 antibodies, we observed that 
SUSP1 was quantitatively shifted into a higher molecular mass 
band within 5 min of incubation with HA-SU2-VS, confi  rming 
this conclusion.
Notably, an HA-reactive band of the same size was only 
weakly seen in the reaction containing HA-SU1-VS, suggesting 
that it has a signifi  cantly lower affi  nity for SUSP1. Although 
some SUSP1 migrated at a higher molecular weight after incu-
bation with HA-SU1-VS, this conversion was signifi  cantly 
slower than in reactions containing HA-SU2-VS and did not 
proceed to completion within 30 min. Together, these results 
suggest that SUSP1 has a strong preference for SUMO2 over 
SUMO1. To test this conclusion using more stringent criterion, 
we preblocked U2OS cell lysates with a threefold molar excess 
(over the VSs) of untagged aldehyde derivatives of SUMO1 
or -2, which bind reversibly to the active sites of SUMO proteases 
(Pickart and Rose, 1986). After blocking, the extracts were 
  allowed to react with HA-SU2-VS and analyzed by Western 
blotting using anti-HA antibodies (Fig. 5). In these experiments, 
SUMO2 aldehyde, but not SUMO1 aldehyde, competed for the 
binding of HA-SU2-VS to SUSP1 and caused reduction in the 
intensity of the HA-reactive band at 160 kD, rigorously sup-
porting the conclusion that SUSP1 has higher affi  nity  for 
SUMO2/3 paralogues.
SUSP1 preferentially cleaves substrates 
with multiple SUMO2 moieties
We developed model substrates to further evaluate the enzy-
matic activity of SUSP1 in processing and deconjugation  assays. 
To examine SUSP1 activity as a processing enzyme, we ex-
pressed SUMO1, -2, and -3 in bacteria, fused at their C termini 
to a T7 tag (SU1-, SU2-, and SU3-T7). We purifi  ed these sub-
strates by affi   nity chromatography. We immunoprecipitated 
SUSP1 from HeLa extracts using anti-SUSP1 antibodies and 
confi  rmed its activity through reactivity with HA-SU2-VS (Fig. 
6 A). We then tested whether the immunoprecipitated SUSP1 
fraction could release the T7 tag from the model processing 
substrates. We observed negligible cleavage of the SU1-, SU2-, 
and SU3-T7 during the course of a 45-min reaction at 37°C 
(Fig. 6 B, bottom), indicating that SUSP1 works poorly as a 
processing enzyme under these conditions.
As a positive control, we performed the same experiment 
using immunoprecipitated SENP1 protein (Fig. 6 A), which has 
been shown to be an effi  cient processing enzyme for SUMO1 
but ineffi  cient in its action against SUMO3 (Xu and Au, 2005). 
We judged that comparable concentrations of active enzyme 
were added to both reactions through equivalent reactivity with 
HA-SU2-VS, which would irreversibly label the active sites of 
both enzymes during the course of a 15-min reaction. Consis-
tent with the earlier fi  ndings, we observed effi  cient cleavage 
of SU1- and SU2-T7 by SENP1, with minimal activity toward 
SU3-T7 (Fig. 6 B, top). Although these results do not strictly 
rule out the possibility that SUSP1 is ever involved in process-
ing of any paralogue, they argue that SUSP1 is unlikely to be a 
major processing enzyme.
To examine deconjugation, we produced a purifi  ed, 
  recombinant C-terminal fragment containing the primary 
  acceptor site Ran GTPase-activating protein 1 (RanGAP1; 
His6-T7-RanGAP1-C2). We incubated this fragment in vitro 
with purifi  ed E1 and E2 enzymes plus SUMO1 or -2 (Azuma 
et al., 2001), resulting primarily in monoconjugated species 
Figure 4.  SUSP1 paralogue preference for SUMO2. Cell lysates from 
SUSP1- or Lamin-depleted cells were incubated with HA-SU1-VS or HA-
SU2-VS for the indicated times. The reactions were terminated with SDS 
sample buffer and analyzed by Western blotting using anti-HA (A) or anti-
SUSP1 antibodies (B).
Figure 5.  SUSP1 preferentially binds to SUMO2 aldehyde. U2OS cell 
  lysates were incubated with 0.3 or 0.9 ng/μl of SUMO1 or SUMO2 alde-
hyde. The samples were then allowed to react with HA-SU1-VS or HA-SU2-VS, 
as indicated, for 5 min. The reactions were terminated with sample buffer 
and analyzed by Western blotting with anti-HA antibodies.JCB • VOLUME 174 • NUMBER 7 • 2006  944
containing each paralogue. We again found that immunoprecip-
itated SUSP1 showed little activity against these model sub-
strates (unpublished data), leading us to conclude that SUSP1 
works poorly as a deconjugating enzyme against substrates con-
taining single SUMO moieties.
These results suggested that SUSP1 might not act as a 
general processing or deconjugation enzyme but might act on a 
much more specialized subset of SUMO2/3-containing sub-
strates. To test whether it might act on substrates that are multi-
ply conjugated, we used polycistronic vectors for bacterial 
expression of His6-T7-RanGAP1-C2 with SUMO E1 and E2 
enzymes, along with SUMO1 or -2 (Uchimura et al., 2004). In 
this system, His6-T7-RanGAP1-C2 becomes highly conjugated 
with the coexpressed SUMO proteins (Fig. 7), as isopeptidases 
are absent. Formation of these conjugates requires the diglycine 
motif at the C termini of SUMO proteins and the primary 
SUMO acceptor lysine of RanGAP1 (Lys517 in Xenopus 
 laevis), indicating that SUMO conjugation in Escherichia coli 
occurs through an isopeptide bond between Lys517 of Ran-
GAP1 and glycine at the C terminus of SUMO1 (Uchimura 
et al., 2004). To this extent, conjugation in E. coli and mamma-
lian cells are similar, as both occur specifi  cally through the sin-
gle, conserved primary acceptor lysine (Mahajan et al., 1998; 
Matunis et al., 1998). This specifi  city is likely to refl  ect the 
strong and specifi  c binding of Ubc9 to this region of RanGAP1 
  (Bernier-Villamor et al., 2002; Reverter and Lima, 2005). It is 
formally possible that conjugation of Lys517 in bacteria pro-
motes the subsequent recognition and conjugation of other 
  lysine residues within His6-T7-RanGAP1-C2. However, we 
consider this scenario to be improbable because none of the 
other lysine residues lie within an optimal sequence context, nor 
do they become conjugated under any other circumstances, in-
cluding in vitro assays with high concentrations of all conjuga-
tion pathway enzymes. Thus, it is most likely that the conjugates 
from E. coli bearing multiple SUMO polypeptides are confi  g-
ured in chains or branched structures.
After bacterial lysis and affi  nity purifi  cation of His6-T7-
RanGAP1-C2–containing species, we obtained a preparation 
containing His6-T7-RanGAP1-C2 conjugated to different num-
bers of SUMO moieties. We assayed whether immunoprecipi-
tated SUSP1 would effectively deconjugate any or all of the 
species contained in this mixture (Fig. 7). We observed that the 
immunoprecipitated SUSP1 fraction cleaved high-molecular-
weight SUMO2 conjugates very effi  ciently. Interestingly, con-
jugation products containing only one or two SUMO2 moieties 
were not effi  ciently deconjugated, even with relatively long in-
cubations (Fig. 7, A and C, 60 min). Remarkably, we observed 
minimal deconjugation of any SUMO1-containing substrates 
(Fig. 7 B), indicating that SUSP1 is also not an effi  cient isopep-
tidase for SUMO1 conjugates, even those that linked to high 
numbers of SUMO1 moieties.
Overall, this pattern indicates that SUSP1 acts preferen-
tially against substrates bearing three or more SUMO2/3 moi-
eties. This conclusion is consistent with the limited change in 
GFP-SUMO2–conjugated substrates after SUSP1 depletion 
(Fig. S2), where we see accumulation of very high molecular 
weight species rather than a global change in the pattern of con-
jugated targets, supporting the notion that SUSP1 dismantles 
SUMO2/3 chains both in vitro and in vivo.
Discussion
We have used a coordinated approach to investigate in vivo func-
tion and in vitro biochemical properties of SUSP1. Our observa-
tions demonstrate that SUSP1 is a nucleoplasmic SUMO2/3 
isopeptidase. The activity of this enzyme is required to maintain 
the distribution of SUMO-conjugated species between subnuclear 
compartments, and we observe the inappropriate accumulation of 
Figure 6. SUMO maturation activity of 
SUSP1. (A) SUSP1, Senp1, and control IgG 
beads were used to immunoprecipitate the 
  respective enzymes from HeLa cell lysate. The 
enzymes bound to the beads were then re-
acted with HA-SUMO2-VS for 15 min. West-
ern blot was performed with the indicated 
antibodies. (B) Full-length SUMO1, -2, or -3 
proteins fused to a T7 tag at their C terminus 
(SU1-, SU2-, and SU3-T7) were expressed in 
bacteria and puriﬁ   ed. These substrates were 
incubated with IgG, Senp1, or SUSP1 beads 
for the indicated times, and Western blotting 
was performed with the indicated antibodies. SUSP1 CLEAVES SUMO2/3 • MUKHOPADHYAY ET AL. 945
SUMO2/3-modifi  ed species in PML bodies and other structures 
in its absence. Moreover, in vitro analysis of paralogue specifi  city 
through VS derivatives of SUMO proteins strongly indicate that 
SUSP1 acts selectively on SUMO2. Further experiments with 
other model substrates revealed that SUSP1 has minimal activity 
as a processing enzyme or in the deconjugation of single SUMO 
moieties. On the other hand, assays of its activity against SUMO-
conjugated substrates that were prepared using an E. coli–based 
expression system showed that SUSP1 could act effectively 
against species conjugated with multiple SUMO2 moieties. 
  Collectively, these observations suggest that SUSP1 plays a 
highly specialized role in vertebrate cells in the dismantling of 
highly conjugated SUMO2/3 species and that the appropriate 
control of these species is critical for the accurate maintenance of 
nuclear structures, particularly PML bodies.
An earlier report indicated that SUSP1 acts as a process-
ing enzyme for SUMO1 in vitro but that it does not effi  ciently 
deconjugate SUMO1 from RanGAP1, leading to the conclusion 
that SUSP1 is primarily involved in SUMO1 processing (Kim 
et al., 2000). In contrast, our observations imply that SUSP1 has 
little processing activity (Fig. 6) but is important for SUMO2/3 
deconjugation, especially from species containing three or more 
SUMO moieties (Fig. 7). This apparent confl  ict may refl  ect the 
fact that Kim et al. (2000) examined neither processing of 
SUMO2/3 nor deconjugation of monomeric or polymeric 
SUMO2/3 species. As a result, SUMO1 processing may have 
appeared to be the most robust activity of this enzyme, even 
though this activity is not substantial in comparison to SUSP1’s 
capacity to dismantle highly conjugated SUMO2/3 species. 
Kim et al. (2000) also reported that SUSP1 localizes to the cy-
toplasm, whereas we fi  nd that the majority of this protein re-
sides within nuclei of HeLa and U2OS cells (Fig. 1). We are 
confi  dent in the conclusion that SUSP1 is a nuclear protein, be-
cause we have used multiple independent methods to assay its 
localization. Mapping of the sequences suffi  cient for targeting 
of SUSP1 defi  nes an N-terminal domain that contains multiple 
putative nuclear localization signals (Fig. 1 D), providing some 
suggestion that SUSP1 gains entry to the nucleus through clas-
sical nuclear import pathways.
Interestingly, we fi  nd that the depletion of SUSP1 alters the 
distribution of EGFP-SUMO2 and -SUMO3, causing marked 
accumulation of these fusion proteins in PML-containing bodies 
(Figs. 2 and 3). It has previously been reported that RNAi-mediated 
depletion of SUMO3 specifi  cally redistributes PML and causes 
loss of PML body integrity (Fu et al., 2005). This defect could 
be rescued by the expression of exogenous wild-type SUMO3, 
but not by a mutant lacking lysine 11, the primary residue impli-
cated in SUMO2/3 chain formation. In combination with our 
fi  ndings, these data suggest that the integrity of PML bodies may 
require the formation of SUMO2/3 chains. Because SUSP1 acts 
to dismantle multiply conjugated species (Fig. 7), its absence 
  after RNAi-mediated depletion promotes not only the accumula-
tion of such species within the PML bodies of cells expressing 
EGFP-SUMO2 or -SUMO3, but also the assembly of PML bod-
ies of remarkably increased size and number.
We have performed genomic searches across eukaryotic 
species to identify SENP/Ulp family members, to perform a 
comparison of their protein sequences (Fig. 8). The SENP8/
Deneddylase 1–related branch of this family tree was clearly 
distinct, consistent with the fi  nding that these enzymes act spe-
cifi  cally on another ubiquitin-like protein, Nedd8 (Gan-Erdene 
et al., 2003; Wu et al., 2003). More notable, we found that an-
other branch point divided the SUMO-specifi  c SENP/Ulp fam-
ily members into two distinct subsets, which contained budding 
yeast Ulp1p and -2p, respectively. Vertebrates possess four en-
zymes within the Ulp1p branch (SENP1, -2, -3, and -5), but 
only two within the Ulp2p branch (SUSP1/SENP6 and SENP7). 
Given this evolutionary relationship, it is interesting to note that 
our data indicate some conservation of function within one of 
these two branches: elegant genetic and biochemical studies 
suggest that the critical function of Ulp2p in budding yeast 
  involves regulation of Smt3p chain elongation (Bylebyl et al., 
2003). Our fi   ndings indicate that SUSP1 acts preferentially 
against multiply conjugated SUMO2/3 species (Fig. 7), which 
are likely to contain chained or branched SUMO structures 
(Uchimura et al., 2004). Moreover, we fi  nd that changes in the 
profi  le of EGFP-SUMO2– or EGFP-SUMO3–conjugated sub-
strates upon SUSP1 depletion are most pronounced among very 
high molecular mass species (Fig. S2), consistent with the pos-
sibility that polymerized EGFP-SUMO2 and -SUMO3 struc-
tures form in its absence, whereas other aspects of SUMO2 and 
-3 metabolism are largely unaltered.
Figure 7.  Preferential SUMO2 chain cleavage by SUSP1. T7-tagged RanGAP-C2 conjugated to either SUMO1 or -2 in E. coli was puriﬁ  ed and incubated 
with SUSP1 beads for the indicated times. The samples were separated by SDS-PAGE and assayed by Western blotting with anti-T7 (A), anti-SUMO1 (B), 
or anti-SUMO2 (C) antibodies. Single and double asterisks indicate conjugated species bearing two and three SUMO moieties, respectively. More highly 
conjugated species are indicated with a bracket.JCB • VOLUME 174 • NUMBER 7 • 2006  946
SENP/Ulps appear to share both the conserved catalytic 
region and a similar overall arrangement, wherein the catalytic 
domains are localized toward the C terminus of each protein and 
targeting sequences are found within their N termini (Melchior 
et al., 2003). Our fi  nding that sequence features required for nu-
cleoplasmic targeting of SUSP1 lie within its N-terminal domain 
is clearly consistent with this pattern (Fig. S1). Two other fea-
tures of SUSP1’s sequence may be further notable in light of its 
strong preference for multiply conjugated SUMO2 and -3 spe-
cies. First, SUSP1 possesses four sequence motifs that conform 
to a previously identifi  ed SUMO-binding domain (Fig. 1 D; 
Song et al., 2004). It is interesting to speculate that these motifs 
may confer a higher affi  nity of SUSP1 for multimeric SUMO2/3 
chains or orient SUSP1 during the process of substrate recogni-
tion. Second, SUSP1 also contains a 195-residue insertion that 
splits the conserved region corresponding to the catalytic do-
main (Fig. S1). This insertion appears to be unique to SUSP1, 
although SENP7 possesses a smaller inserted sequence in a 
closely equivalent confi  guration. We do not yet know the func-
tion of this inserted sequence, although it is possible to speculate 
that it may either enhance SUSP1’s activity against polymeric 
SUMO2/3 or restrict SUSP1’s activity against other targets, in-
cluding single SUMO conjugates or processing substrates.
The most extensive analysis of SENP/Ulp functions have 
been performed in budding yeast (Li and Hochstrasser, 1999, 
2000, 2003; Bylebyl et al., 2003); these studies have conclu-
sively shown that Ulp1p and -2p are not functionally redundant, 
as elimination of either protein results in highly distinct pheno-
typic consequences. We believe that vertebrate SENP/Ulps may 
possess an even higher degree of specialization with respect 
to their enzymatic activity, paralogue preference, and targeted 
  localization within the nucleus. In this case, it will be vital to 
characterize each of these enzymes accurately and completely, 
in order to interpret experiments involving their manipulation 
correctly and to understand fully their role within the whole 
SUMO pathway.
Materials and methods
Antibodies and reagents
Monoclonal mouse antibody (PG-M3) against PML was obtained from 
Santa Cruz Biotechnology, Inc. SUSP1 antibody was raised in rabbit 
against the N-terminal 499 amino acid of SUSP1 and was afﬁ  nity puriﬁ  ed 
using an antigen column. Anti-HA 3F10 rat monoclonal antibody was pur-
chased from Roche Diagnostics Corporation. Alexa Fluor–labeled second-
ary antibodies were obtained from Invitrogen, HRP-conjugated mouse and 
rabbit secondary antibodies and N-hydroxysuccinimide–Sepharose (FF) 
were obtained from GE Healthcare, HRP-conjugated anti-rat antibody was 
obtained from Pierce Chemical Co., and HRP-conjugated anti-T7 tag anti-
body was obtained from Novagen (EMD Biosciences). Anti-SUMO1, 
-SUMO2, and -Senp1 polyclonal antibodies were raised in rabbit and af-
ﬁ  nity puriﬁ  ed (provided by M. Matunis, Johns Hopkins University School of 
Public Health, Baltimore, MD). All other reagents were obtained from 
Sigma-Aldrich unless otherwise stated.
DNA constructs
pEGFP and pDsRed vectors were obtained from CLONTECH Laboratories, 
Inc. Restriction enzymes were purchased from New England Biolabs, Inc. 
DNA primers and Platinum Taq Hi Fi DNA polymerase were obtained 
from Invitrogen.
Full-length (unprocessed) human SUMO1, -2, and -3; mature 
  SUMO1GG, SUMO2GG, and SUMO3GG (with diglycine at amino acid 
positions 96–97, 92–93, and 90–91, respectively); and nonconjugatable 
SUMO1G, SUMO2G, and SUMO3G (with a single C-terminal glycine at 
Figure 8.  Evolutionary relationship of SENP/
Ulp family members. The eukaryotic genome 
databases of National Center for Biotechnol-
ogy Information were searched using psi-
BLAST using human SENP protein sequences 
and query with e-value inclusion cutoff of 
0.001, for 6–10 cycles. Whenever any spe-
ciﬁ  c genome of interest failed to give any hit, 
the nucleotide genome sequence of corre-
sponding organism was searched using 
TBLASTN with human Senp protein sequences 
as query. The collected protein sequences 
were aligned using MUSCLE (Edgar, 2004) 
with 100 iterations. The generated multiple 
alignments were manually corrected using the 
conserved C48 peptidase domain as anchor. 
Phylogenetic analyses were performed using 
the minimum evolution (least-square) method 
as implemented in MEGA3.1 (Kumar et al., 
2004), with Poisson correction model and 
pairwise deletion of gaps and 1,000 boot-
strap replicates. For each protein sequence, 
the letters indicate the shortened binomial no-
menclature, and the numbers indicate the pro-
tein GenBank accession nos. Asterisks indicate 
sequences that are not in GenBank.SUSP1 CLEAVES SUMO2/3 • MUKHOPADHYAY ET AL. 947
amino acid positions 96, 92, and 90, respectively) coding sequences 
were subcloned into HindIII and BamHI restriction sites of pEGFP-C3. Full-
length SUSP1 was cloned into XhoI and BamHI sites of either pEGFP-NI or 
-C2 by RT-PCR from HeLa cell total RNA. Deletion fragments of SUSP1 were 
ampliﬁ  ed by PCR using speciﬁ  c primers and cloned into XhoI and BamHI 
sites of pEGFP-N1.
The rescue SUSP1 plasmid was prepared by sense-antisense method 
of site-directed mutagenesis using the primer set 5′-G  A  A  G  A  A  T  C  T  G  A  A  G  G-
G  G  A  T  A  C  A  -3′, 5′-T  T  C  A  T  G  A  T  C  A  A  A  G  C  T  C  C  A  A  T  T  -3′, which incorporates 
three sense point mutations at 124 bp (A to T), 125 bp (G to C), and 132 
bp (A to G) from the start of the open reading frame and generates a BciVI 
restriction site. This was then subcloned into XhoI and BamHI restriction 
sites of pDSRed-Mono-N1 vector. The absence of any unintended muta-
tions was conﬁ   rmed for all constructs by DNA sequencing (SeqWright 
DNA Technology Services).
Cell culture
HeLa cells, U2OS cells, and their derivative stable lines were grown at 
37°C in a humidiﬁ  ed atmosphere of 5% CO2 in DME (Biosource Interna-
tional) with 2 mM glutamine supplemented with 10% fetal bovine serum 
(Gemini Bio-Products), 100 U penicillin/ml, and 100 μg/ml streptomycin. 
Cells were transfected with plasmids using Effectene reagent (QIAGEN) 
according to the manufacturer’s instructions.
siRNA-mediated depletion of SUSP1
For transient transfections, cells were grown to 50% conﬂ  uency and Effec-
tene reagent (QIAGEN) was used according to the manufacturer’s instruc-
tions. Duplex siRNA directed against SUSP1 and Lamin A/C messages 
were obtained from QIAGEN. SUSP1 and Lamin A/C siRNA sequences 
were 5′-A  A  G  A  A  A  G  T  G  A  A  G  G  A  G  A  T  A  C  A  G  -3′ and 5′-A  A  C  T  G  G  A  C  T  T  C  C  A  G-
A  A  G  A  A  C  A  -3′, respectively, with standard dTdT 3′ extension.
siRNA experiments were performed in 24-well culture plates, coverslip-
bottomed 4-well chambers (LabTekII; Fisher Scientiﬁ  c), or 6-cm dishes. Cells 
were allowed to attach overnight at 40% conﬂ  uency and washed once 
with DME without antibiotics immediately before transfection of siRNA. 
3 μl siRNA (20 μM) and 3 μl of oligofectamine (Invitrogen) were sus-
pended in 50 and 12 μl of OptiMEM (Invitrogen), respectively, in separate 
tubes. The tubes were gently tapped and kept at RT for 5 min, and the con-
tents of the two tubes were mixed, kept at RT for a further 20 min, and 
added to a single well of 24-well plate or a well of 4-well chamber contain-
ing 0.5 ml complete DME without antibiotics. For the 6-cm dish, the same 
procedure was followed but the reagents were scaled up to four times.
Production and maintenance of stable cell lines
For stable cell line selection, 0.5 mg/ml Geneticin was added to culture 
  medium 24 h after transfection. Cells were incubated in Geneticin-containing 
culture medium that was refreshed daily for a period of 1 wk after resistant 
colonies were reseeded sparsely to culture single cell–derived colonies. 
  Uniformly ﬂ  uorescent colonies derived from single cells were marked and 
isolated under an inverted ﬂ  uorescence microscope. Stably transgenic cells 
were maintained thereafter in medium containing 0.25 mg/ml Geneticin.
Immunoﬂ  uorescence
Cells were grown either on poly-L-lysine–coated coverslips or LabTekII 
  coverslip-bottomed chambers. For immunoﬂ   uorescence, the cells were 
washed with PBS and ﬁ  xed for 12 min at ambient temperature with 4% 
paraformaldehyde in PME buffer (PBS supplemented with 5 mM each of 
MgCl2 and EGTA). The cells were permeabilized with 0.5% Triton X-100 
for 10 min. After washing with PME, the cells were blocked for 10 min in 
1% normal horse serum (Vector Laboratories) in PME and incubated for 
1 h with anti-PML antibodies diluted 1:200 in blocking solution. The coverslips 
were washed and incubated for 45 min with Alexa Fluor 568–conjugated 
secondary antibodies (Invitrogen) diluted 1:400 in blocking solution. 
  Unbound antibodies were removed by washing, and the cells were brieﬂ  y 
incubated in 100 ng/ml Hoechst 33258 DNA stain. Finally, the coverslips 
were mounted in Vectashield mounting medium (Vector Laboratories).
Microscopy
Fluorescence microscopy was performed on a confocal microscope 
(LSM510 META; Carl Zeiss MicroImaging, Inc.) equipped with 40× Plan 
Neoﬂ  uar objective. LabTekII coverslip-bottomed chambers were used for 
live analyses. Temperature (37°C) and CO2 concentration (5%) were main-
tained using a humidiﬁ  ed environmental chamber. Confocal microscopy 
software (SP2 version 3.2; Carl Zeiss MicroImaging, Inc.) was used for 
capturing images, which were then analyzed by Photoshop 7.0 (Adobe). 
In all ﬁ  gures, scale bars represent 10 μm.
Illumination of samples for ﬂ  uorescent imaging
We used a 543-nm HeNe laser (5 mW output; detection LP560 nm) for 
  detection of RFP-SUSP1-rescue signal and indirect immunolocalization of 
PML by Alexa Fluor 568–labeled antibodies. The 488-nm line of an Argon 
laser (25 mW nominal output; detection BP 505–530 nm) were used for 
analysis of GFP-conjugated proteins. Hoechst 33258 images were cap-
tured using the 364-nm line of an ion laser (Enterprise II ML UV [Coherent, 
Inc.]; 80 mW nominal output; detection BP 385–470 nm).
Synthesis of SUMO derivatives
Expression of SUMO-intein-CBD fusion proteins in E. coli was as described 
in Hemelaar et al., (2004). Bacterial lysates were prepared as described 
previously (Hemelaar et al., 2004) and bound to chitin bead columns 
(New England Biolabs, Inc.). The columns were washed with ﬁ  ve volumes 
of lysis buffer (50 mM Hepes, 100 mM sodium acetate, pH 6.5, and 
50 μM PMSF), followed by three volumes of lysis buffer containing 50 mM 
β-mercaptoethanesulfonic acid (MESNa; Sigma-Aldrich). The column was 
incubated overnight at 37°C in the buffer with MESNa to allow on-column 
cleavage. The SUMO-MESNa thiolesters were eluted with 1.5 column 
  volumes of lysis buffer, and the fractions containing SUMO-MESNa pro-
ducts were concentrated on a Centriprep (3,000-molecular-weight cutoff; 
Millipore). To convert SUMO-MESNa products to their VS derivatives, a 
large excess of Glycine VS (ﬁ  nal concentration 0.25 M) was added to con-
centrated SUMO-MESNa (1–3 mg/ml; 500 μl), followed by addition of 
75 μl of 2 M N-hydroxysuccinimide and 30 μl of 2 M NaOH (provided 
by H. Ovaa, Netherlands Cancer Institute, Amsterdam, Netherlands; 
Hemelaar et al., 2004). The mixture was incubated for 1–2 h at 37°C, and 
the reaction was terminated by the addition of 30 μl of 2 M HCl.
To obtain SUMO1 and -2 aldehydes, SUMO1 and -2 acetals were 
synthesized by reacting SUMO-MESNa thiolesters (1–3 mg/ml; 500 μl) 
with 0.2 ml of 4 M aminoacetaldehyde diethyl acetal, pH 8.5, and 0.14 ml 
of N-hydroxysuccinimide, pH 7.0, at 37°C for 2 h. To obtain SUMO1 
and -2 aldehydes, SUMO1 and -2 acetals were separately incubated with 
0.15 M HCl at 37°C for 30 min. All steps of derivative syntheses were 
monitored by HPLC and by SDS-PAGE.
SUMO derivatives were puriﬁ   ed by ion exchange chromatogra-
phy, desalted on PD10 columns, and dialyzed into 50 mM Triethanol-
amine, pH 6.5. SUMO1 and -2 aldehydes were further puriﬁ  ed  by 
adsorbing on an anion exchange column (Mono Q HR; Pharmacia) equili-
brated with 50 mM TEA, pH 6.5, and eluted with a linear gradient 
of NaCl from 0 to 0.5 M (ﬂ  ow rate of 0.75 ml/min; fraction size = 1 ml). 
For puriﬁ   cation of HA-SUMO1-VS and HA-SUMO2-VS on Mono Q, 
50 mM Bis-Tris, pH 5.5, was used, with a gradient from 0 to 0.15 M 
NaCl. In all cases, proteins were monitored by absorbance at 205 nm. 
Individual Mono Q fractions were assayed by HPLC, and appropriate 
fractions were pooled and stored at −80°C.
HA-SUMO-VS experiments
VS and aldehyde derivatives of SUMO1 and -2 were prepared as 
  described previously (Hemelaar et al., 2004). 48 h after transfection with 
siRNAs directed against Lamin or SUSP1, as indicated, U2OS cells were 
harvested and washed twice in PBS containing 1 mM AEBSF. The cells 
were resuspended in reaction buffer (10 mM Hepes, pH 7.4, 150 mM 
NaCl, 5 mM EDTA, 1 mM DTT, and 25 μg/ml each of leupeptin, aprotinin, 
and pepstatin) and sonicated. Cell lysates were clariﬁ  ed by centrifugation 
at 16,000 g for 10 min. The protein concentration of the total cell lysate 
was maintained between 500 μg/ml and 2 mg/ml. SUMO-VS was added 
to a ﬁ  nal concentration of 0.3 ng/μl and allowed to react for the indicated 
intervals. The reactions were terminated by the addition of SDS sample 
buffer and analyzed by Western blotting with the indicated antibodies.
SUMO deconjugation assay
SUMO1- and SUMO2-conjugated (His)6-T7-RanGAP-C2 fragment were pro-
duced in bacteria (Uchimura et al., 2004) and puriﬁ  ed using Ni-NTA beads 
(provided by Y. Uchimura and H. Saitoh, Kumamoto University, Kumamoto, 
Japan). SUSP1 was immunoprecipitated from HeLa cell lysate using anti-
body conjugated to N-hydroxysuccinimide–Sepharose (2 μg/ml of beads). 
10 μl SUSP1 beads were incubated with 500 ng of SUMO-conjugated 
T7-RanGAP-C2 in a total reaction volume of 30 μl at 23°C for the indicated 
times. The reaction was terminated with sample buffer and analyzed by 
Western blotting with antibodies against T7, SUMO1, or SUMO2/3.
Preparation of SUMO processing substrates
Full-length SUMO1, -2, and -3 cDNAs were subcloned into pET28b ex-
pression plasmids that had been cut with NcoI–NdeI, NcoI–NdeI, and 
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transfected into E. coli, and the expression of the fusion proteins was 
  induced with 0.4 mM IPTG under standard conditions. The expressed 
C-  terminally tagged SUMO-T7-His proteins were puriﬁ   ed on a Ni-NTA 
  column followed by Q-Sepharose and MonoQ columns to generate pure 
tagged substrate for the processing reactions.
SUMO processing assay
HeLa cells from conﬂ  uent 15-cm dishes were harvested by trypsinization 
and washed twice with ice-cold PBS. The cells were snap frozen in liquid 
nitrogen and then sonicated in 500 μl lysis buffer (10 mM Hepes, pH 
7.5, 150 mM NaCl, 1 mM DTT, 1 mM AEBSF, and 5 mg/ml each of leu-
peptin, pepstatin, and aprotinin). The cell lysates were centrifuged at 
120,000 rpm for 5 min at 2°C. The cleared supernatants were incubated 
with 5 μg of rabbit IgG, afﬁ  nity-puriﬁ  ed anti-SENP1 antibody, or afﬁ  nity-
puriﬁ  ed anti-SUSP1 antibody for 1 h at 4°C. 50 μl preblocked protein 
A beads were added to the lysates and incubated for another hour and 
subsequently washed three times in lysis buffer. The beads were reacted 
with 0.3 ng/μl HA-SUMO2-VS in lysis buffer containing 100 μg/ml BSA 
for 15 min at RT, and the reactions were terminated with sample buffer. 
Using the different dilutions of the HA-SUMO-VS adducts thus obtained, 
beads having an equivalent enzymatic activity for SENP1 and SUSP1 
were determined by anti-HA Western blot. Beads having equivalent 
amount of HA-SUMO2-VS reactivity and control beads were then incu-
bated with 40 ng/μl SUMO1, -2 or -3 T7 for different time points at 23°C 
in 20 μl reaction volume. The reactions were stopped by the addition of 
sample buffer, and Western blots were performed using anti-T7, -SUMO1, 
or -SUMO2/3 antibodies.
Evolutionary relationship of SENP/Ulp family members
The eukaryotic genome databases of the National Center for Biotechnol-
ogy Information were searched using psi-BLAST using human Senp protein 
sequence and query with e-value inclusion cutoff of 0.001, for 6–10 
  cycles. Whenever any speciﬁ  c genome of interest failed to give any hit, the 
nucleotide genome sequence of corresponding organism was searched us-
ing TBLASTN with human Senp protein sequences as query. The collected 
protein sequences were aligned using MUSCLE (Edgar, 2004) with 100 
  iterations. The generated multiple alignments were manually corrected 
  using the conserved C48 peptidase domain as anchor. Phylogenetic ana-
lyses were performed using minimum evolution (least-square) method as 
implemented in MEGA3.1 (Kumar et al., 2004), with Poisson correction 
model and pairwise deletion of gaps and 1,000 bootstrap replicates.
Online supplemental material
Fig. S1 shows aligned sequences of Ulp1p and Ulp2p/Smt4p from 
S. cerevisiae and mammalian SENP/Ulp family members. Fig. S2 shows 
EGFP-SUMO3 in SUSP1-depleted cells. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200510103/DC1.
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